Table 2.

Cumulative incidence of patients with ≥ 1 FRAX^®-defined major osteoporotic fracture and adjusted hazard ratios estimated with an extended Cox regression model at different time points of follow-up

	Teriparatide (n = 680)	Risedronate (n = 680)	HR (95% CI)	p value
At 3 months	4 (0.6%)	4 (0.6%)	0.62 (0.27, 1.41)	0.251
At 6 months	9 (1.4%)	12 (1.8%)	0.52 (0.27, 1.02)	0.057
At 7 months	9 (1.4%)	17 (2.6%)	0.50 (0.26, 0.93)	0.030
At 8 months	9 (1.4%)	18 (2.8%)	0.47 (0.26, 0.86)	0.015
At 9 months	9 (1.4%)	19 (3.0%)	0.45 (0.24, 0.81)	0.008
At 12 months	10 (1.5%)	24 (3.8%)	0.38 (0.20, 0.72)	0.003
At 15 months	12 (1.9%)	28 (4.4%)	0.32 (0.14, 0.71)	0.005
At 18 months	14 (2.2%)	33 (5.3%)	0.27 (0.10, 0.74)	0.011
At 21 months	15 (2.4%)	36 (5.8%)	0.23 (0.07, 0.79)	0.020
At 24 months	16 (2.6%)	40 (6.4%)	0.20 (0.05, 0.86)	0.031

BMD, bone mineral density; CI, confidence interval; HR, hazard ratio (teriparatide versus risedronate). Adjusted by treatment, antecedent of recent clinical vertebral fracture, recent use of bisphosphonate, age, baseline femoral neck BMD, baseline 25-hydroxy-vitamin D concentration, geographical region, and time-varying covariate treatment-by-time interaction